deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02302157

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Sponsor: Lineage Cell Therapeutics, Inc.

Conditions Cervical Spinal Cord Injury Spinal Cord Trauma Spine Injury
Interventions AST-OPC1
Updated 21 times since 2017 Last updated: Jul 12, 2021 Started: Mar 31, 2015 Primary completion: Dec 31, 2018 Completion: Dec 31, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02302157, this PHASE1/PHASE2 trial focuses on Cervical Spinal Cord Injury and Spinal Cord Trauma and remains completed. Sponsored by Lineage Cell Therapeutics, Inc., it has been updated 21 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Jul 2020 · 11 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

▶ Show 16 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Sep 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE1_PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jul 2020 — Aug 2020 [monthly]

    Completed PHASE1_PHASE2

  6. Aug 2019 — Jul 2020 [monthly]

    Completed PHASE1_PHASE2

  7. Mar 2019 — Aug 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  8. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  14. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  15. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lineage Cell Therapeutics, Inc.
Data source: Lineage Cell Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations